Fiche publication
Date publication
juin 2026
Journal
International journal of radiation oncology, biology, physics
Auteurs
Membres identifiés du Cancéropôle Est :
Dr MIRJOLET Céline
,
Pr TRUC Gilles
,
Pr DENAT Franck
,
Dr COLLIN Bertrand
,
Pr COCHET Alexandre
,
Dr BELLAYE Pierre-Simon
,
Dr DIAS Alexandre
Tous les auteurs :
Bellaye PS, Tavares A, Ladjohounlou R, Moreau M, Bernhard C, Dias A, Claron M, Froidurot L, Guillemin M, Collin B, Denat F, Truc G, Cochet A, Baude J, Mirjolet C
Lien Pubmed
Résumé
Colorectal cancer (CRC) remains one of the most prevalent and lethal malignancies worldwide. Although external beam radiotherapy (RT) plays a growing role in primary and metastatic CRC, dose escalation may remain limited due to the high dose received by neighboring organs which may cause toxicity. Targeted Radionuclide Therapy (TRT) selectively delivers cytotoxic radiation to tumor cells through a molecular vector that targets a specific protein overexpressed by cancer cells, and is linked to a therapeutic radionuclide. The present study aims to provide proof-of-concept for combining in vivo RT with anti-PDL1-targeted TRT delivered via an anti-PDL1 antibody.
Mots clés
Colorectal cancer, Combination therapy, anti-PDL1, radiotherapy, targeted radionuclide therapy
Référence
Int J Radiat Oncol Biol Phys. 2026 06 26;:
